Medtronic Heart Valve Division

  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    SATP
  • 2 Events

2 devices in the database

  • Model / Serial
    LS-EnVeoR-23 | 7332506
  • Product Description
    MD: Heart valve bioprosthesis, animal-derived
  • Model / Serial
    LS-ENVEOR-23 and LS-ENVEOR-2629 | see FSN
  • Product Classification
  • Product Description
    MD: Heart valve bioprosthesis, animal-derived

One manufacturer with a similar name

Learn more about the data here

  • Manufacturer Address
    Medtronic Heart Valve Division, 8299 Central Ave Ne, Spring Lake Park MN 55432-2023
  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    USFDA